The B2B Podcast Index
Index
All categories
MarketingSalesSaaSFinanceHROpsLeadershipCustomer SuccessAI & DataProductStartups & FoundersRevOpsEngineering & DevTools
MethodologySubmit
Best of:MarketingSalesSaaSFinanceHROpsLeadershipCustomer SuccessAI & DataProductStartups & FoundersRevOpsEngineering & DevTools
An independent project byFame
SearchBest episodesGuestsInsightsMethodologySubmit a podcast
Index/Leadership/The Innovators Studio with Phil McKinney
The Innovators Studio with Phil McKinney artwork

How to Improve Weak Signal Judgment

The Innovators Studio with Phil McKinney · 2026-06-24 · 13 min

0:00--:--

Key moments - from our scoring

Substance score

44 / 100

Five dimensions, 20 points each

Insight Density11 / 20
Originality10 / 20
Guest Caliber8 / 20
Specificity & Evidence10 / 20
Conversational Craft5 / 20

Most organizations now collect weak signals through newsletters, trend reports, and AI tools, but collecting signals generates zero competitive advantage. The edge belongs to those willing to act on faint evidence before certainty arrives - because by the time something is certain, everyone sees it and the price has moved. McKinney draws on his experience on Roche Diagnostics' innovation board, where the team correctly identified both the rise of Type 2 diabetes and the shift toward continuous glucose monitoring, yet failed to move fast enough because annual budget cycles and project approval processes rewarded only proven ideas. The discipline involves three learnable skills: distinguishing a canary (a behavior revealing an irreversible customer need) from a costume (a temporary fad), finding the narrow window where the signal remains deniable but actionable, and - most critically - structuring small bets where being wrong costs only a week of resources while being right puts you a year ahead. McKinney argues that noticing is now commoditized; the competitive advantage lies in judgment and nerve. He offers a practical exercise: pick one dismissed behavior, determine if it's canary or costume, assess how much longer it stays deniable, design a prototype-scale test, and execute it. He's also released 'From Signal to Bet,' an AI-prompt toolkit available at innovation.tools to guide this analysis.

Key takeaways

  • →Weak signals are predictions, not things to spot - the edge goes to whoever bets on it while being wrong is still cheap, not whoever collects the most reports.
  • →The three core moves are: distinguish canaries (irreversible structural shifts) from costumes (temporary fads) by identifying the underlying need; read the window by acting while the signal is still deniable but before competitors catch on; and design cheap bets where failure costs a week but success puts you a year ahead.
  • →Annual budgets and project approval processes in large organizations kill weak signal execution by funding only what's already proven, causing companies like Roche to correctly predict major shifts (Type 2 diabetes growth, continuous monitoring) but fail to move fast enough.
  • →Most people collecting signals never act on them because noticing carries no risk and builds no muscle for small-scale commitment; they confuse caution with safety and call inaction foresight.
  • →The skill to practice is designing bets so small (a prototype, landing page, two-week sprint) that being early and wrong costs nothing while being early and right compounds over years.

Topics in this episode

Roche DiagnosticsWeak signalsCanary versus costume frameworkContinuous glucose monitoringAccuCheck metersType 2 diabetes trendsSignal-to-action windowCheap bets and prototype testingFrom Signal to Bet (AI prompts toolkit)Innovation.tools

Questions this episode answers

What's the difference between a canary and a costume in weak signal reading?

A canary signals structural change that affects everyone in an environment - a customer need they cannot reverse once started. A costume is striking behavior that spreads briefly then disappears, like a fad. Both look identical on day one; the discipline is reading for the underlying need, not the noise of how fast it spreads.

Why did Roche miss the Type 2 diabetes opportunity despite seeing the signals?

Roche correctly predicted both the rise of Type 2 diabetes and the shift to continuous monitoring, but project approval and annual budget cycles were built to fund only proven ideas, not faint signals. They waited for the next budget cycle to make it safe, costing them years of competitive advantage.

When should you act on a weak signal if waiting for more evidence makes you wrong?

The value lives in the narrow gap between being too early (noise drowns the signal) and too late (everyone sees it). By the time you have enough evidence to feel certain, competitors have already seen it too. The question isn't whether the signal is real yet - it's how much longer you can be the only one taking it seriously.

How do you structure a bet so being wrong is cheap?

Instead of committing a product line or big budget to a deniable signal, commit small: a prototype, landing page, one conversation with ten customers, or a two-week sprint. Being early and wrong should cost about a week; being early and right should put you a year ahead.

What's the practical exercise to train weak signal judgment?

Pick one dismissed behavior, run it through three moves - identify if it's canary or costume by naming the underlying need in one sentence, assess how much longer it stays deniable, then design the smallest test you could run this month where failure costs a week. Then execute that one real signal.

What our scoring noted

Our reviewer’s read on each dimension, with quotes from the episode.

Insight Density

11 / 20

The episode contains a handful of genuinely sharp reframes - positioning a weak signal as a prediction rather than an observation, and arguing that deniability is the strategic feature not a bug. However, the middle section fills time with the Roche story and the closing third is self-promotional padding, dragging down the ideas-per-minute count noticeably.

A weak signal isn't a thing to spot. It's a prediction you make.
The noticing got automated. What didn't get automated is the judgment about which signal is predicting structural change and which signals point to nothing real.

Originality

10 / 20

The deniability-as-feature framing and the 'cheap bet' structuring argument are genuinely crisp and somewhat underexplored in mainstream innovation writing, but the canary-vs-costume fad/trend distinction is decades old and the overall framework stays firmly within conventional innovation-consulting territory rather than offering first-principles or contrarian surprises.

it's that deniability is the whole point. The moment it becomes undeniable that that is obvious evidence that's going to happen, the advantage is gone and the price has moved.
You're not betting on being right. You're buying the option to be right.

Guest Caliber

8 / 20

This is a solo monologue; there is no guest. The host has legitimate practitioner credentials - an innovation board seat at Roche Diagnostics as an outsider member - but the episode surfaces only one limited case study and relies heavily on aphorism rather than deep operational detail, so the credibility present in the room is only partially cashed out.

I sat on Roche's, Roche the big medical company, on their innovation board for what's called Roche Diagnostics. This is all the test meters and et cetera. I was the only outsider in the room, helping decide which ideas got funded.
I had literally hundreds of meters. And I picked my finger up to a dozen times a day to feel what their customers felt.

Specificity & Evidence

10 / 20

The Roche/AccuCheck diabetes story is the sole concrete anchor and does include real product names and a meaningful data point about testing frequency; however, the episode offers no outcome metrics, no timeline for when signals were seen vs. when CGM launched, and no external evidence beyond the single anecdote, leaving the frameworks essentially unvalidated.

Someone with type 1 diabetes tests around eight times a day, every day, for the rest of their life.
AccuCheck, SmartGuide, it's real-time continuous monitor is on the market.

Conversational Craft

5 / 20

As a solo monologue there is no interviewer, no questions, no follow-up, and no productive friction whatsoever; the episode closes with a direct product pitch for a paid digital download, which further undercuts any sense of disinterested craft. The structure is clean but that is presentation skill, not conversational skill.

One of my quotes that I say all the time, and you're probably tired of hearing it, ideas without execution as a hobby.
If you want a sparring partner for that, I've built one for you. From Signal to Bet is a digital download. It's a set of AI prompts that run a signal through these same three moves and argues with you for you to read at each one. It's free over at innovation.tools or down in the link below.

Conversation analysis

Computed from the transcript - who did the talking, and the words that came up most.

Most-used words

signal18wrong9read8early7signals6cheap6evidence6already6three6roche6type6weak5noise5noticing5change5test5

Episode notes

Everyone collects weak signals now. Most of what they collect predicts nothing. A weak signal isn't a thing you spot, it's a prediction you make, and the edge goes to whoever bets on it while being wrong is still cheap. So how do you become the one placing the bet, not the one still collecting reports? Let's get into it. What a Weak Signal Actually Is A weak signal is a faint piece of evidence that points to something a customer will want before they can name it, and before the market has priced it in. Faint, because if it were loud, everyone would already be acting on it. Deniable, because you can always explain it away as noise, and most people do. That deniability is the whole point. The moment it becomes undeniable, the advantage is gone and the price has moved. Why Noticing Stopped Being the Edge Ten years ago, noticing was hard. You needed sources, a network, time to read widely, a feel for the edges of your industry. That was the moat. It isn't anymore. Every team has a trend report and three newsletters and an AI tool surfacing emerging behaviors on a schedule. The noticing got automated.

Full transcript

13 min

Transcribed and scored by The B2B Podcast Index.

Everyone collects weak signals now, but most of what they collect predicts nothing. A weak signal isn't a thing to spot. It's a prediction you make. And the edge goes to whoever bets on it while being wrong is still cheap.

So how do you become the one placing the bet, not the one still collecting all those reports? Let's get into it. A weak signal is a faint piece of evidence that points to something a customer will want before they can even name it. And before the market has priced it in.

It's faint because if it were loud, everyone would already be acting on it. It still needs to be deniable because you can always explain it away as noise. And most people do. It's that deniability is the whole point.

The moment it becomes undeniable that that is obvious evidence that's going to happen, the advantage is gone and the price has moved. Ten years ago, noticing was hard. You needed sources, a network, time to read widely, a feel for the edges of your industry. That was the moat.

I remember I would read literally 100 plus magazines a month. I've written about this and I've done a podcast episode on it. probably 15 years ago, if you want to go search back through the archive. And that was the moat of the time.

It isn't anymore. Every team has trend reports and three newsletters and an AI tool that services emerging behaviors on a regular schedule. The noticing got automated. What didn't get automated is the judgment about which signal is predicting structural change and which signals point to nothing real.

and the nerve to act early. Let me tell you a little background. I sat on Roche's, Roche the big medical company, on their innovation board for what's called Roche Diagnostics. This is all the test meters and et cetera.

I was the only outsider in the room, helping decide which ideas got funded. At one point, we took on diabetes care. Now, I'm not a diabetic. So I had Roche ship me every meter and every test strip combination they made.

I had literally hundreds of meters. And I picked my finger up to a dozen times a day to feel what their customers felt. Because my belief is you cannot innovate for a customer whose day you have not lived in. Skip that and everything you're trying to do is a guess.

Roche was a leader in blood glucose testing with its AccuCheck meters. And the math for their business looked obvious. Someone with type 1 diabetes tests around eight times a day, every day, for the rest of their life. A big stable business Type 2 diabetes was the smaller story per patient Those patient tested once maybe twice a day So each one looked worth less to Roche and we filed the category under less interesting.

We could already see type 2 climbing. We waited against the per patient math and explained it away. Now, then type 2 diabetes exploded into one of the fastest growing chronic conditions in the world. And the category stopped being about counting tests per day at all because the monitoring went continuous.

The always-on sensors that you see people wearing on their arms today. We had seen the early edge of both shifts. We even predicted them. We just couldn't move fast enough.

And the reason the one that kills most weak signals inside of the big company, and that is project approval and annual budgets are built to fund what's already proven not to chase something faint. Roast now did get there. AccuCheck, SmartGuide, it's real-time continuous monitor is on the market. But I just wish we had moved the moment we saw it instead of waiting for the next budget cycle to make it safe.

So how do you read a weak signal? We didn't miss the type 2 signal for lack of noticing. We noticed. We missed it on the three things that come after.

And these are the three you can train. The move starts once you got the signal you can't quite dismiss. And the skill is what to do with it. First up, you got to be able to tell the canary from the costume.

Now, the canary in the coal mine was used by coal miners to predict air quality. And it matters because the air would change. And if you saw the canary change, it told the coal miners, get out of that space. It signals something structural, a shift in the environment that affects everyone in it, whether they've noticed it yet or not.

A costume is the opposite. A few people put it on, it's striking, it spreads for a season, then they take it off and the room is exactly as it was. On day one, the two looked identical. A behavior appears.

It's unusual. It's spreading. The only question that matters is whether it predicts a change in the customers cannot reverse. Once they start down that change, they will not come back.

Or is this a moment that will just pass? It's a fad. Now, back in 2018, I wrote about telling a trend from a fad, and the test still holds. Ask what need the behavior reveals.

Type 2 was a canary and we read it as a costume because we counted testing frequency instead of the need underneath it That need millions of people learning to manage a lifestyle disease only grew The discipline is refusing to let the size of the spike tell you which one you looking at. Costumes spike too, sometimes even higher because everybody hops on the bandwagon, and follow the leader, you're reading for the need, not the noise. The next is read the window. A signal's window is short.

Too early and you can't tell from the noise and you waste resources chasing ghosts. Too late, it's obvious, everyone sees it, and the advantage is already priced in. The value lives in that narrow gap in between. Waiting for more evidence feels like better judgment.

But the evidence that finally convinces you has already reached your competitors. Certainty and advantage move in opposite directions. So by the time you're sure, sure is just another word for you're too late. The question isn't whether the signal is real or yet.

It's how much longer you can be the only one taking it seriously. Waiting is not your advantage. But then that gets you into the third step. Act while being wrong is still cheap.

This is the move that separates the people who read signals from those who collect them. And almost nobody is willing to make it. A signal you predict but never act on is still watching. One of my quotes that I say all the time, and you're probably tired of hearing it, ideas without execution as a hobby.

And I don't know about you, but I'm not in the hobby business. The whole value of an early signal is that you move before it's confirmed. Wait for proof and you're waiting too long. So you have to act on thin evidence and you got to get comfortable with this.

And let's face it, thin evidence is wrong a lot, which means you will be wrong a lot and that's fine. But people hear that and they freeze because they picture the cost of being wrong as that big failed product launch or that wasted year or the budget burned on a gas. People call that caution. It isn't.

The skill is structuring the bet so that being wrong is cheap. You don't commit a product line to a deniable signal. You commit a prototype, a landing page, one conversation with 10 customers, a two-week test that costs you a sprint and buys you information you cannot get any other way. Being early and wrong should cost you about a week.

Being early and right should put you a year ahead of your competitors. You're not betting on being right. You're buying the option to be right. cheap enough that being wrong doesn hurt and you scale up only as the signal firms up That why the noticing crowd never gets here Noticing carries no risk so it never builds the muscle for cheap commitment.

They watch, they report, they wait for certainty, and they call that foresight. It's the safe choice and its value is zero. So let's talk about how do you practice this? How do you do something with this to actually exercise it?

So pick one behavior you've been dismissing as noise in your customers, in your product idea that you're working on, on a blank idea, come up with something. But what's that one behavior you've been dismissing as noise? something you've seen more than once. Maybe it's your customers, your kids, your own habits that you've waved off because it looked too small or too strange to matter.

Then run it through the three moves. Is it a canary or a costume? What need is the behavior revealing? A need the person can't go back from or a novelty they'll sit down next season?

Write the answer in one sentence. If you can't, you don't understand the signal yet. Step two, find the window. How much longer does this stay deniable?

Who else is likely seeing it? If the honest answer is it already feels obvious, pick a different signal. You're late on that one. Step three, design the cheap bet.

What's the smallest thing you could do this month to test whether you're right? Where being wrong costs you a week, being right puts you ahead. Name the bet. Name the cost.

Name what you're going to learn from this. Then do this one real signal and you'll feel the difference between collecting signals and using them. Collecting is comfortable. Using one costs you a decision.

If you want a sparring partner for that, I've built one for you. From Signal to Bet is a digital download. It's a set of AI prompts that run a signal through these same three moves and argues with you for you to read at each one. It's free over at innovation.

tools or down in the link below. The exercise teaches you the moves. The prompts makes you defend them. This is your partner to argue against.

The signal was always there for you and for everyone reading the same reports you read. The edge was never in seeing it. It was in what you were willing to do before it was safe to do anything at all. Get good at that and you stop reacting to the future and you start arriving early.

We'll see you next week. Bye bye.

Related episodes across the Index

Other episodes covering the same guests and topics, from across The B2B Podcast Index.

  • Operational Resilience, Risk Management and Crisis Decision-Making with Bruce McIndoeRiskMasters · on Weak signals87 / 100
  • Focus, validation, and the future of women's health: A conversation with Jill Angelo of OuraStartUp Health NOW Podcast · on Continuous glucose monitoring79 / 100
  • The Question Behind the Question - Field Training with Jennifer MuszikPharma Sessions · on Roche Diagnostics67 / 100
  • Leadership Retreats: Mistakes to Avoid Part 2Informed Decisions · on Weak signals54 / 100

More from The Innovators Studio with Phil McKinney

All episodes →
  • How to Improve Your Second-Order Thinking Skills
  • How to Improve Your Inversion Thinking Skills
  • How to Overcome Expert Bias
  • How to Improve Your First Principles Thinking
  • How to Overcome Confirmation Bias
Explore the best B2B Leadership podcasts →
All The Innovators Studio with Phil McKinney episodes →